Podocalyxin: A marker of blasts in acute leukemia

American Journal of Clinical Pathology

Volumn 124, Issue 1, 2005, Pages 134-142

  Kelley, Todd W ^a   Huntsman, David ^b   McNagny, Kelly M ^b   Roskelley, Calvin D ^b   Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Acute leukemia; CD34; Myeloid sarcoma; Podocalyxin; WT1

Indexed keywords

CD34 ANTIGEN; PODOCALYXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MESOTHELIUM; NEPHROBLASTOMA; PODOCYTE; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 21744441931     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/7BHLAHHU0N4MHT7Q     Document Type: Article

References (23)

1. Krause DS, Fackler MJ, Civin CI, et al. CD34: structure, biology, and clinical utility. Blood. 1996;87:1-13.
2. Strauss LC, Rowley SD, La Russa VF, et al. Antigenic analysis of hematopoiesis, V: characterization of my-10 antigen expression by normal lymphohematopoietic progenitor cells. Exp Hematol. 1986;14:878-886.
3. McNagny KM, Pettersson I, Rossi F, et al. Thrombomucin, a novel cell surface protein that defines thrombocytes and multipotent hematopoietic progenitors. J Cell Biol. 1997;138:1395-1407.
4. Kerosuo L, Juvonen E, Alitalo R, et al. Podocalyxin in human haematopoietic cells. Br J Haematol. 2004;124:809-818.
5. Kerjaschki D, Sharkey DJ, Farquhar MG. Identification and characterization of podocalyxin: the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol. 1984;98:1591-1596.
6. Kershaw DB, Thomas PE, Wharram BL, et al. Molecular cloning, expression, and characterization of the podocalyxin-like protein 1 from rabbit as a transmembrane protein of glomerular podocytes and vascular endothelium. J Biol Chem. 1995;270:29439-29446.
7. Schopperle WM, Kershaw DB, DeWolf WC. Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun. 2003;300:285-290.
8. Kershaw DB, Beck SG, Wharram BL, et al. Molecular cloning and characterization of human podocalyxin-like protein: orthologous relationship to rabbit PCLP1 and rat podocalyxin. J Biol Chem. 1997;272:15708-15714.
9. Sassetti C, Van Zante A, Rosen SD. Identification of endoglycan, a member of the CD34/podocalyxin family of sialomucins. J Biol Chem. 2000;275:9001-9010.
10. Doyonnas R, Kershaw DB, Duhme C, et al. Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med. 2001;194:13-27.
11. Fieger CB, Sassetti CM, Rosen SD. Endoglycan, a member of the CD34 family, functions as an L-selectin ligand through modification with tyrosine sulfation and sialyl Lewis x. J Biol Chem. 2003;278:27390-27398.
12. Sassetti C, Tangemann K, Singer MS, et al. Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: parallels to CD34. J Exp Med. 1998;187:1965-1975.
13. Palmer RE, Kotsianti A, Cadman B, et al. WT1 regulates the expression of the major glomerular podocyte membrane protein podocalyxin. Curr Biol. 2001;11:1805-1809.
14. Guo JK, Menke AL, Gubler MC, et al. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet. 2002;11:651-659.
15. Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia. 1995;9:1060-1067.
16. Iizuka Y, Aiso M, Oshimi K, et al. Myeloblastoma formation in acute myeloid leukemia. Leuk Res. 1992;16:665-671.
17. Byrd JC, Edenfield WJ, Shields DJ, et al. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol. 1995;13:1800-1816.
18. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours.
19. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern. Med. 1985;103:620-625.
20. Somasiri A, Nielsen JS, Makretsov N, et al. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res. 2004;64:5068-5073.
21. Algar E, Blackburn D, Kromykh T, et al. Mutation analysis of the WT1 gene in sporadic childhood leukaemia. Leukemia. 1997;11:110-113.
22. Miyagawa K, Hayashi Y, Fukuda T, et al. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies. Genes Chromosomes Cancer. 1999;25:176-183.
23. King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood. 1998;91:2961-2968.